| Literature DB >> 35117747 |
Junbiao Huang1,2, Changwei Lin1, Yifei Chen3, Xiaorong Li1.
Abstract
BACKGROUND: In clinical practice, we often encounter patients with concurrent papillary thyroid carcinoma (PTC) and nodular goitre (NG). What are the similarities and differences between these patients and patients with simple NG? Whether NG-related nodules can affect the occurrence and development of PTC still remains unknown.Entities:
Keywords: Papillary thyroid carcinoma (PTC); body mass index; nodular goitre
Year: 2020 PMID: 35117747 PMCID: PMC8798884 DOI: 10.21037/tcr-19-2951
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Characteristics of patients with nodular goitre, nodular goitre & papillary thyroid carcinoma and papillary thyroid carcinoma
| Variable | NG (n=317) | PTC (n=183) | NG&PTC (n=74) | P |
|---|---|---|---|---|
| Age (years) | 47.19±12.03 | 40.38±10.40 | 45.54±12.06 | <0.001 |
| <55, n (%) | 235 (74.1) | 172 (94.0) | 59 (79.7) | |
| ≥55, n (%) | 82 (25.9) | 11 (6.0) | 15 (20.3) | <0.001 |
| Sex, n (%) | ||||
| Male | 70 (22.1) | 64 (35.0) | 16 (21.6) | |
| Female | 247 (77.9) | 119 (65.0) | 58 (78.4) | 0.004 |
| Residence location, n (%) | ||||
| Rural | 201 (63.4) | 97 (53.0) | 36 (48.6) | |
| Urban | 116 (36.6) | 86 (47.0) | 38 (51.4) | 0.015 |
Potential risk factors for papillary thyroid carcinoma occurrence in nodular goitre patients
| Risk factors | NG (n=317) | NG&PTC (n=74) | P value |
|---|---|---|---|
| Age (years) | 47.19±12.03 | 45.54±12.06 | 0.290 |
| <55 | 235 (74.1%) | 59 (79.7%) | |
| ≥55 | 82 (25.9%) | 15 (20.3%) | 0.315 |
| Sex | |||
| Male | 70 (22.1%) | 16 (21.6%) | |
| Female | 247 (77.9%) | 58 (78.4%) | 0.931 |
| Residence location | |||
| Rural | 201 (63.4%) | 36 (48.6%) | |
| Urban | 116 (36.6%) | 38 (51.4%) | 0.019 |
| BMI | 23.17±3.23 | 23.89±3.53 | 0.094 |
| <24 | 204 (64.4%) | 35 (47.3%) | |
| ≥24 | 113 (35.6%) | 39 (52.7%) | 0.007 |
| BMIF | |||
| <24 | 172 (69.6%) | 32 (55.2%) | |
| ≥24 | 75 (30.4%) | 26 (44.8%) | 0.035 |
| BMIM | |||
| <24 | 32 (45.7%) | 3 (18.8%) | |
| ≥24 | 38 (54.3%) | 13 (81.3%) | 0.048 |
| BSA | 1.61±0.16 | 1.63±0.14 | 0.353 |
| BSAF | 1.57±0.11 | 1.59±0.10 | 0.159 |
| BSAM | 1.80±0.16 | 1.80±0.13 | 0.862 |
| Hashimoto thyroiditis (HT) | |||
| Y | 5 (1.6%) | 4 (5.4%) | |
| N | 312 (98.4%) | 70 (94.6%) | 0.122 |
Comparison of thyroid function measured by the Centaur® XP immunoassay system between the nodular goitre patients and nodular goitre & papillary thyroid carcinoma patients
| Risk factor | NG (n=224) | NG&PTC (n=58) | P value |
|---|---|---|---|
| FT3 | 3.18±0.48 | 3.16±0.57 | 0.758 |
| FT4 | 1.27±0.67 | 1.48±1.81 | 0.400 |
| TSH | 1.75±2.69 | 2.08±2.44 | 0.397 |
Comparison of thyroid function measured by the Cobas e601 test immunoassay analyser between the nodular goitre patients and nodular goitre & papillary thyroid carcinoma patients
| Risk factor | NG (n=93) | NG&PTC (n=16) | P value |
|---|---|---|---|
| FT3 | 5.12±1.01 | 4.97±0.84 | 0.565 |
| FT4 | 16.24±3.00 | 15.31±5.18 | 0.494 |
| TSH | 1.89±1.51 | 2.61±1.73 | 0.090 |
Univariate logistic regression analysis of risk factors for papillary thyroid carcinoma in the nodular goitre patients
| Selected variable | b | Sb | P | OR | 95% CI |
|---|---|---|---|---|---|
| Female | −0.027 | 0.313 | 0.931 | 0.973 | 0.527–1.798 |
| Age ≥55 years | 0.317 | 0.316 | 0.371 | 1.372 | 0.738–2.551 |
| Residence in an urban area | −0.604 | 0.260 | 0.020 | 0.547 | 0.328–0.910 |
| BSA | 0.762 | 0.819 | 0.352 | 2.142 | 0.430–10.654 |
| Presence of HT | −1.271 | 0.684 | 0.062 | 0.280 | 0.073–1.071 |
| BMI ≥24 | −0.699 | 0.261 | 0.007 | 0.497 | 0.298–0.829 |
Multivariate logistic regression analysis of risk factors for papillary thyroid carcinoma in the nodular goitre patients
| Selected variable | b | Sb | P | OR | 95% CI |
|---|---|---|---|---|---|
| Female | −0.112 | 0.427 | 0.794 | 0.894 | 0.387–2.066 |
| Age ≥55 years | 0.385 | 0.329 | 0.243 | 1.469 | 0.770–2.802 |
| Residence in an urban area | −0.719 | 0.271 | 0.008 | 0.487 | 0.287–0.829 |
| BSA | −0.767 | 1.386 | 0.580 | 0.464 | 0.031–7.020 |
| Presence of Hashimoto thyroiditis (HT) | −1.353 | 0.715 | 0.058 | 0.258 | 0.064–1.049 |
| BMI ≥24 | −0.865 | 0.346 | 0.012 | 0.421 | 0.214–0.829 |
Impact of nodular goitre on papillary thyroid carcinoma progression
| Factors | PTC | NG&PTC | P value |
|---|---|---|---|
| Number of cancer nodules | |||
| Single | 128 (69.9%) | 64 (86.5%) | |
| Multiple | 55 (30.1%) | 10 (13.5%) | 0.006 |
| Cancer nodule size | |||
| ≤1 cm | 111 (60.7%) | 49 (66.2%) | |
| >1 cm | 72 (39.3%) | 25 (33.8%) | 0.405 |
| Extra-glandular invasion | |||
| N | 166 (90.7%) | 67 (90.5%) | |
| Y | 17 (9.3%) | 7 (9.5%) | 0.966 |
| Lymph node metastasis | |||
| N | 123 (67.2%) | 63 (85.1%) | |
| Y | 60 (32.8%) | 11 (14.9%) | 0.004 |
| Central lymph node metastasis | |||
| N | 131 (71.6%) | 65 (87.8%) | |
| Y | 52 (28.4%) | 9 (12.2%) | 0.006 |
| Lateral lymph node metastasis | |||
| N | 166 (90.7%) | 71 (95.9%) | |
| Y | 17 (9.3%) | 3 (4.1%) | 0.156 |